Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants - PubMed
4 hours ago
- #SGLT2 inhibitors
- #heart failure prevention
- #genetic cardiomyopathy
- SGLT2 inhibitors, like dapagliflozin, reduce heart failure hospitalizations more effectively in carriers of pathogenic cardiomyopathy gene variants (HR 0.18) than in non-carriers (HR 0.70).
- The absolute risk reduction for heart failure hospitalization was 13.0% in carriers versus 1.0% in non-carriers, with most carriers having no prior heart failure history.
- The study suggests early SGLT2 inhibitor use may prevent heart failure in individuals with cardiomyopathy-associated genetic variants, based on data from the DECLARE-TIMI 58 trial.